Equashield Hosts Safe Handling Summit for International Oncology Pharmacy Professionals
PORT WASHINGTON, New York, Dec. 4, 2017
Equashield, a leading provider of Closed System Transfer Devices (CSTDs) for the safe and simple handling of hazardous drugs, announced hosting a first-of-its-kind Safe Handling Summit, where pharmacy professionals from 14 countries met to exchange knowledge and learn from industry leaders about recent developments in the CSTD market.
Summit attendees, including 25 hospital pharmacists, pharmacy purchasing decision makers, industry Key Opinion Leaders (KOLs), as well as international distributors from across Europe, Asia and North America, discussed safe handling practices, the CSTD competitive landscape, and strategies for new market penetration. Additionally, several KOLs delivered presentations on key issues related to the FDA’s ONB product code and the NIOSH protocols for testing the efficacy of the various CSTDs on the market.
“We see significant value in learning from pharmacy professionals whose sole focus is increasing the safe handling of hazardous drugs,” said Adi Shor, VP, Sales, ROW for Equashield. “Attendees shared experience and knowledge from their home markets, and gained insight from the various lectures and case studies presented. We also toured Equashield’s manufacturing facility, which includes new state-of-the-art automation technology, and showcased the Equashield Pro – the market’s first closed system drug compounding robot.”
Flay Charbonneau, Pharmacy Manager for Sunnybrook Health Sciences Centre in Toronto, Canada, gave a presentation on, “The ONB Product Code and Drug Vial Optimization.”
“Equashield’s Safe Handling Summit was an important opportunity to learn from other distributors. I left the meeting excited to make an impact in the coming year,” said Ian Churchill, National Sales Manager for Australian distributor REM Systems. “We are confident in Equashield’s product, and, after hearing further perspectives from industry KOLs, we believe this is the top CSTD that compounding pharmacists should be using.”
“It was eye opening to learn more about the competitive landscape, and we gained a greater understanding of the regulatory realities in the safe handling market,” said Anna Wieczorek, Pharmacist for NU-MED Center for Diagnostic and Oncology Therapy, Tomaszow Mazowiecki, Poland. “We were also impressed with Equashield’s manufacturing facility; it is clear the company has invested to ensure they are delivering the safest CSTD to the market.”
Equashield is a leading provider of a full range of manual and automated solutions to hospitals for the compounding and administration of hazardous drugs. Equashield’s product suite includes EQUASHIELD II, its flagship Closed System Transfer Device (CSTD), and EQUASHIELD® Pro, the first ever closed system drug compounding robot. Equashield’s CSTD is clinically-proven to protect healthcare professionals from hazardous drug exposure. The globally awarded EQUASHIELD® II covers more routes of exposure than alternative systems by preventing contamination of syringe plungers and drug residuals on connector surfaces, as well as exposure to drug vapors. Studies have shown Equashield’s CSTD to be faster to deploy and easier to use than competing systems, and the system has passed the proposed 2015 alcohol vapor containment protocol from NIOSH, confirming that it can contain the harshest vapors and emissions. EQUASHIELD is in use by hundreds of hospitals and clinics around the world, and has been both cleared by the FDA under the ONB product code, and substantiated in FDA-cleared labeling as preventing microbial ingress for up to seven days.